# Association between brain volume and depression in Alzheimer's disease: Neuroimaging insights

**Authors:** Chao Tang, Jiaxin Yang, Xiaoyang Lei, Ming Zhang, Yi Chen, Xiaoxue Peng, Dian He

PMC · DOI: 10.1002/alz.71120 · 2026-01-29

## TL;DR

This study finds that hippocampal atrophy in Alzheimer's patients is linked to depression, suggesting that brain volume changes may explain the connection between the two conditions.

## Contribution

The study identifies hippocampal atrophy as a mediator between depression and Alzheimer's disease.

## Key findings

- AD patients had significantly higher rates of depressive symptoms compared to controls.
- Hippocampal atrophy mediated the relationship between depression and AD.
- Reduced hippocampal volume correlates strongly with cognitive impairment severity.

## Abstract

Alzheimer's disease (AD) often co‐occurs with depression, affecting cognitive function and quality of life. Understanding the neurobiological links between brain abnormalities and depressive symptoms is essential for effective treatment.

We analyzed 2,722 participants from the National Alzheimer's Coordinating Center, including 886 AD patients and 1,836 cognitively normal controls. Neuroimaging assessed brain volumes, while depressive symptoms were measured using the Geriatric Depression Scale. Multiple linear regression and mediation analyses evaluated associations between brain structure, cognitive function, and depression.

AD patients had significantly higher rates of depressive symptoms (35.3% vs. 14.7%; p < 0.001) and cognitive impairments (mean Mini‐Mental State Examination [MMSE]: 23.1 vs. 28.9; p < 0.001). Hippocampal atrophy mediated the relationship between depression and AD (indirect effect = −0.107; p < 0.001).

Hippocampal atrophy significantly mediates the relationship between depression and AD, suggesting targeted interventions may enhance patient outcomes.

Alzheimer's disease (AD) patients show significant hippocampal atrophy linked to depression.Reduced hippocampal volume correlates strongly with cognitive impairment severity.Depression occurrence is higher in AD, impacting overall patient quality of life.Neurological pathways connecting depression and brain changes warrant further study.Targeted interventions may improve cognitive and emotional health in AD patients.

Alzheimer's disease (AD) patients show significant hippocampal atrophy linked to depression.

Reduced hippocampal volume correlates strongly with cognitive impairment severity.

Depression occurrence is higher in AD, impacting overall patient quality of life.

Neurological pathways connecting depression and brain changes warrant further study.

Targeted interventions may improve cognitive and emotional health in AD patients.

## Linked entities

- **Diseases:** Alzheimer's disease (MONDO:0004975), depression (MONDO:0002050)

## Full-text entities

- **Genes:** APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}
- **Diseases:** small vessel disease (MESH:D059345), and frontal cortical atrophy (MESH:D001284), frontotemporal dementia (MESH:D057180), neuronal injury (MESH:D009410), Dementia (MESH:D003704), fatigue (MESH:D005221), Lewy body dementia (MESH:D020961), neurotoxic (MESH:D020258), white matter (MESH:D056784), psychiatric (MESH:D001523), neurodegeneration (MESH:D019636), lateralized ventricular dilation (MESH:C566255), impairments in memory, language, and executive functions (MESH:D007806), Neuroinflammation (MESH:D000090862), ventricular enlargement (MESH:D006332), Stroke (MESH:D020521), brain atrophy (MESH:C566985), schizophrenia (MESH:D012559), MCI (MESH:D060825), inflammatory (MESH:D007249), mood disorders (MESH:D019964), Neurological and Communicative Disorders (MESH:D003147), brain abnormalities (MESH:D001927), ML (MESH:D007859), vascular depression (MESH:D000088323), Neuroanatomical abnormalities (MESH:D000014), edema (MESH:D004487), bipolar disorder (MESH:D001714), ischemia (MESH:D007511), vascular dementia (MESH:D015140), cognitive and emotional dysfunctions (MESH:D003072), anhedonia (MESH:D059445), RESEARCH (MESH:D014947), Depression (MESH:D003866), Alzheimer (MESH:D000544), hippocampal volume loss (MESH:D000092223)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12854940/full.md

---
Source: https://tomesphere.com/paper/PMC12854940